Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity
Journal for ImmunoTherapy of Cancer · 2025-10 · 13 (10) · e012182
DOI: 10.1136/jitc-2025-012182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 05.10.2025. Verfasst von Haiyang Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology o…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Interleukin-1beta, Macrophages, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, AstraZeneca, Global Horizontal Project.
Abstract (Originalsprache)
Background
Despite the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC), patient outcomes vary even among those with identical EGFR mutations. This study investigates whether osimertinib, a third-generation EGFR-TKI, activates the nucleotide-binding oligomerization domain-like receptor protein-3 (NLRP3) inflammasome in macrophages to drive antitumor immunity and explores its mechanistic basis.
Methods
Using bone marrow-derived macrophages from wild-type and gene-deficient mice, human peripheral blood mononuclear cells, and a Lewis lung cancer murine model, we assessed osimertinib-induced NLRP3 inflammasome activation, interleukin (IL)-1β secretion, pyroptosis, and tumor microenvironment (TME) remodeling. Mechanistic studies evaluated lysosomal dysfunction, calcium overload, mitochondrial damage, and reactive oxygen species (ROS) production. Clinical correlations were analyzed in patients with NSCLC treated with EGFR-TKIs.
Results
Osimertinib triggered NLRP3 inflammasome activation in macrophages via lysosomal dysfunction-induced calcium overload, leading to mitochondrial damage and ROS production, which acted as damage-associated molecular patterns to activate NLRP3. This process promoted IL-1β release, pyroptosis, and CD8 + T-cell activation while suppressing regulatory T cells in the TME. In murine models, osimertinib’s antitumor effects were abrogated by NLRP3 inhibition (MCC950) and enhanced by recombinant IL-1β (rIL-1β) co-administration (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
- CAS Centre for Excellence in Cell and Molecular Biology, University of Science and Technology of China, Hefei, China.
- Department of Medical Oncology, Anhui Provincial Hospital, Hefei, China.
- Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China.
- Department of Pathology, The First Affiliated Hospital of USTC, Hefei, Anhui, China qianxj@ustc.edu.cn panyueyin@ustc.edu.cn sunyubei@ustc.edu.cn wuhaibo@ustc.edu.cn.
- Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China qianxj@ustc.edu.cn panyueyin@ustc.edu.cn…
Förderung
- National Natural Science Foundation of China
- AstraZeneca
- Global Horizontal Project
- USTC Research Funds of the Double First-Class Initiative
Zitieren
APA
Yu, H., Sun, X., Li, Y., Pan, J., Liu, X., He, H., Wu, H., Sun, Y., Pan, Y., & Qian, X. (2025). Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity. Journal for ImmunoTherapy of Cancer, 13(10), e012182. https://doi.org/10.1136/jitc-2025-012182
Vancouver
Yu H, Sun X, Li Y, Pan J, Liu X, He H, et al. Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity. Journal for ImmunoTherapy of Cancer. 2025;13(10):e012182. doi:10.1136/jitc-2025-012182
BibTeX
@article{Yu2025,
author = {Yu, Haiyang and Sun, Xin and Li, Yan and Pan, Jing and Liu, Xuemei and He, Hongbin and Wu, Haibo and Sun, Yubei and Pan, Yueyin and Qian, Xiaojun},
title = {Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {10},
pages = {e012182},
doi = {10.1136/jitc-2025-012182}
}
EUVIMED